Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 208

The DOI matches its Crossref record; 5 of the 5 references it cites were found in a registry or an index.

Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells

Open access
Lu, Yuhong, Zi, Xiaolin, Pollak, Michael·2004·International Journal of Cancer

Abstract

The clinical usefulness of trastuzumab (Herceptin; Genentech, San Francisco, CA) in breast cancer treatment is limited by the rapid development of resistance. We previously reported that IGF‐I signaling confers resistance to the growth‐inhibitory actions of trastuzumab in a model system, but the underlying molecular mechanism remains unknown. We used SKBR3/neo cells (expressing few IGF‐I receptors) and SKBR3/IGF‐IR cells (overexpressing IGF‐I receptor) as our experimental model. IGF‐I antagonized the trastuzumab‐induced increase in the level of the Cdk inhibitor p27 Kip1. This resulted in decreased association of p27 Kip1 with Cdk2, restoration of Cdk2 activity and attenuation of cell‐cycle arrest in G 1 phase, all of which had been induced by trastuzumab treatment in SKBR3/IGF‐IR cells. We also found that the decrease in p27 Kip1 induced by IGF‐I was accompanied by an increase in expression of Skp2, which is a ubiquitin ligase for p27 Kip1, and by increased Skp2 association with p27 Kip1. A specific proteasome inhibitor (LLnL) completely blocked the ability of IGF‐I to reduce the p27 Kip1 protein level, while IGF‐I increased p27 Kip1 ubiquitination. This suggests that the action of IGF‐I in conferring resistance to trastuzumab involves targeting of p27 Kip1 to the ubiquitin/proteasome degradation machinery. Finally, specific inhibitors of MAPK and PI3K suggest that the IGF‐I‐mediated reduction in p27 Kip1 protein level by increased degradation predominantly involves the PI3K pathway. Our results provide an example of resistance to an antineoplastic therapy that targets one tyrosine kinase receptor by increased signal transduction through an alternative pathway in a complex regulatory network. © 2003 Wiley‐Liss, Inc.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1002/ijc.11445

Cites

5 of 5 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 5 references

Cited by

See all 208

Metadata

Authors
Lu, Y., Zi, X., & Pollak, M.
Venue
International Journal of Cancer
Publisher
Wiley
Published
2003-10-28
Volume
108
Issue
3
Pages
334-341
ISSN
  • 0020-7136 (ISSN-L)
  • 1097-0215
OpenAlex
W2033595975
Cited by
208
References
5
FWCI
6.37
Type
journal article
Language
en
Open access
bronze

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. https://app.cochat.ai/papers/10.1002/ijc.11445
The paper
Lu, Y., Zi, X., & Pollak, M. (2004). Molecular mechanisms underlying IGF‐I‐induced attenuation of the growth‐inhibitory activity of trastuzumab (Herceptin) on SKBR3 breast cancer cells. International Journal of Cancer. https://doi.org/10.1002/ijc.11445

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.